Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade

Background. Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR.

Aim. To improve recommendations regarding HER2-targeted agents and chemotherapy in the neoadjuvant treatment of BC.

Materials and methods. N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia took participation in some clinical trials of neoadjuvant treatment of HER2-positive breast cancer, including NeoSphere and NeoALTTO. In multicenter, open-label, phase 2 randomised NeoSphere trial, patients with locally advanced, inflammatory, or early-stage HER2-positive BC were randomly assigned to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus docetaxel (75 mg/m² from every 3 weeks, increasing to 100 mg/m² from cycle 2 if tolerated) (group A), pertuzumab (420 mg every 3 weeks) and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab (group C), or pertuzumab and docetaxel (group D). After surgery, patients received three cycles of FEC. Рatients in group C received four cycles of docetaxel prior to FEC, and trastuzumab 6 mg/kg every 3 weeks to complete 1 years treatment. In NeoALTTO trial from 455 patients 154 patients received lapatinib, 149 – trastuzumab, 152 – combination of lapatinib and trastuzumab.

Results. Between 2007, and 2009, 417 patients were randomly assigned to group A (107 patients), group B (n = 107), group C (n = 107), or group D (n = 96). At clinical cutoff, 87 patients had disease progression or died. 5-year progressionfree survival rates were 81 % (95 % confidence interval (CI) 71–87) for group A, 86 % (95 % CI 72–91) for group B, 73 % for group C, and 73 % for group D (95 % CI 0.34–1.40). Disease-free survival rates were consistent with progressionfree survival rates and were 81 % (95 % CI 72–88) for group A, 84 % (95 % CI 72–91) for group B, 80 % (95 % CI 70–86) for group C, and 75 % (95 % CI 64–83) for group D. In NeoALTTO trial patients who achieved pCR had longer progressionfree survival (85 % (95 % CI 76–91)) compared with patients who did not achieve pCR (76 % (95 % CI 71–81)).

Conclusion. High levels of progression-free survival and disease-free survival at 5–10-years follow-up show large and overlapping CI, but support the primary endpoint (pCR) and suggest that neoadjuvant pertuzumab is beneficial when combined with trastuzumab and docetaxel. Additionally, they suggest that pCR could be an early indicator of long-term outcome in early-stage HER2-positive BC.

1. Semiglazov V.F., Krivorotko P.V., Semiglazov V.V. et al. Organpreserving, reconstructive and systemic treatment of breast cancer. Moscow: SIMK, 2022. 176 p. (In Russ.).

2. Gianni L., Eiermann W., Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375(9712):377–84. DOI: 10.1016/S0140-6736(09)61964-4

3. Swain S.M., Baselga J., Kim S.B. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372(8):724–34. DOI: 10.1056/NEJMoa1413513

4. Gianni L., Pienkowski T., Semiglazov V. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17(6):791–800. DOI: 10.1016/S1470-2045(16)00163-7

5. Baselga J., Bradbury I., Semiglazov V. et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379(9816):633–40. DOI: 10.1016/S0140-6736(11)61847-3. Erratum in: Lancet 2012;379(9816):616.

6. Robidoux A., Tang G., Rastogi P. et.al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomized phase 3 trial. Lancet Oncol 2013;14(12):1183–92. DOI: 10.1016/S1470-2045(13)70411-X

7. Guarneri V., Dieci M.V., Griguolo G. et al. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. Eur J Cancer 2021;153:133–41. DOI: 10.1016/j.ejca.2021.05.018

8. Bianchini G., Kiermaier A., Bianchi G.V. et al. Biomarker analysis of the NeoSphere study: Pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res 2017;19(1):16. DOI: 10.1186/s13058-017-0806-9

9. Huober J., Holmes E., Baselga J. et al. Survival outcomes of the NeoALTTO study (BIG 1-06): Updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019;118:169–77. DOI: 10.1016/j.ejca.2019.04.038

10. Scaltriti M., Nuciforo P., Bradbury I. et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 2015;21(3):569–76. DOI: 10.1158/1078-0432.CCR-14-1824

11. Spring L.M., Fell G., Arfe A. et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin Cancer Res 2020;26(12):2838–48. DOI: 10.1158/1078-0432.CCR-19-3492

12. Cortazar P., Zhang L., Semiglazov V. et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 201;384(9938):164–72. DOI: 10.1016/S0140-6736(13)62422-8

13. Piccart-Gebhart M., Holmes E., Baselga J. et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016;34(10):1034–42. DOI: 10.1200/JCO.2015.62.1797

14. Guarneri V., Frassoldati A., Bottini A. et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 2012;30(16):1989–95. DOI: 10.1200/JCO.2011.39.0823

15. Guarneri V., Dieci M.V., Griguolo G. et al. Trastuzumab–lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. Eur J Cancer 2021;153:133–41. DOI: 10.1016/j.ejca.2021.05.018

16. Minnibaeva A.R., Artamonova E.V., Zhulikov Ya.A. et al. Neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2-positive early or locally advanced breast cancer. Meditsinskiy alfavit = Medical Alphabet 2023;(36):24–9. (In Russ.). DOI: 10.33667/2078-5631-2023-36-24-29

17. Curigliano G., Burstein H.J., Gnant M. et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol 2023;34(11):970–86. DOI: 10.1016/j.annonc.2023.08.017